We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-16.47%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$2.31B
AUM Growth
-$332M
Cap. Flow
+$217M
Cap. Flow %
9.38%
Top 10 Hldgs %
100%
Holding
10
New
2
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
AXLA
Axcella Health Inc. Common Stock
AXLA
+$111M
2
TMDX icon
Transmedics
TMDX
+$69.1M
3
MCRB icon
Seres Therapeutics
MCRB
+$42.2M

Top Sells

Rank Stock Value
1
QTRX icon
Quanterix
QTRX
+$5.31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$861M 37.27%
58,807,379
– –
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
$602M 26.07%
38,296,526
– –
KLDO
3
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$201M 8.72%
17,360,710
– –
DNLI icon
4
Denali Therapeutics
DNLI
$3.67B
$166M 7.19%
8,005,747
– –
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$164M 7.09%
911,670
– –
AXLA
6
DELISTED
Axcella Health Inc. Common Stock
AXLA
$81.4M 3.53%
+349,937
New +$111M
TMDX icon
7
Transmedics
TMDX
$2.5B
$73.4M 3.18%
+2,530,275
New +$69.1M
MCRB icon
8
Seres Therapeutics
MCRB
$48.1M
$69.5M 3.01%
1,078,588
+444,444
+70% +$42.2M
QTRX icon
9
Quanterix
QTRX
$173M
$61.7M 2.67%
1,825,412
-205,083
-10% -$5.31M
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$29.7M 1.28%
320,444
– –

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q2 2019 Portfolio in Review

As of Q2 2019, Flagship Pioneering held 10 positions worth $2.31B, down 13% from $2.64B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering deployed $217M of net new capital in Q2 2019, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Axcella Health Inc. Common Stock: 349,937 shares worth $81.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Quanterix, an estimated $5.31M trimmed.

  • Flagship Pioneering's largest Q2 2019 buy was Axcella Health Inc. Common Stock: 349,937 shares worth $81.4M.
  • Flagship Pioneering added most to Seres Therapeutics in Q2 2019, an estimated $42.2M increase.
  • Flagship Pioneering's biggest Q2 2019 reduction was Quanterix, cutting an estimated $5.31M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $2.31B portfolio in Q2 2019.
  • Flagship Pioneering opened 2 new positions and closed 0 in Q2 2019.
  • Flagship Pioneering's portfolio value fell 13% quarter-over-quarter to $2.31B.

Based on Flagship Pioneering's 13F filing for Q2 2019, filed 13 Aug 2019.